| Learn the main components of each treatment. |
View online |
|
|
|
 |
| Indicated for congenital hemophilia A or B with inhibitors, congenital Factor VII deficiency, Glanzmann’s thrombasthenia with refractoriness to platelets, and acquired hemophilia. See full indication below. |
|
|
|
| Success Speaks for Itself | Hospital Series |
| Lower volume. Faster infusion. |
| Compared to to FEIBA®, patients living with CHwI save time on every infusion.1,2,a |
| To help maximize efficiency in your hospital, everything needed for reconstitution is included in 1 box. |
|
Faster to infuse
than FEIBA®1,2,b,c |
NovoSeven® RT
(90 mcg/kg)a |
FEIBA®
(75 U/kg)d |
|
|
|
|
|
|
|
| 16x less infusion volume than FEIBA®1,2,b,c |
NovoSeven® RT
(90 mcg/kg)a |
FEIBA®
(75 U/kg)d |
|
|
|
|
|
| aAdminister as a slow bolus injection over 2 to 5 minutes, depending on the dose administered. |
| bIn patients with hemophilia A or B with inhibitors. |
| cIndividual doses are compared and based on an 88-kg (194-lb) person. |
| dPatients are cautioned that the maximum injection or infusion rate must not exceed 10 units per kilogram of body weight per minute. |
|
|
|
| Keep scrolling to learn more. |
 |
|
| Selected Important Safety Information |
| WARNING: THROMBOSIS |
| • |
Serious arterial and venous thrombotic events following administration
of NovoSeven® RT have been reported
|
|
| • |
Discuss the risks and explain the signs and symptoms of thrombotic and
thromboembolic events to patients who will receive
NovoSeven® RT
|
|
| • |
Monitor patients for signs or symptoms of activation of the coagulation
system and for thrombosis
|
|
|
| Warnings and Precautions |
| • |
Serious arterial and venous thrombotic events have been reported in clinical trials
and postmarketing surveillance
|
|
| • |
Patients with congenital hemophilia receiving concomitant treatment with aPCCs
(activated prothrombin complex concentrates), older patients particularly with
acquired hemophilia and receiving other hemostatic agents, and patients with a
history of cardiac and vascular disease may have an increased risk of developing
thrombotic events
|
|
| Please click here or scroll below for additional Important Safety Information. |
|
|
|
|
|
| The NovoSeven® RT Difference |
|
| NovoSeven® RT is indicated for bleed control and surgery in: |
 |
CHAwI |
|
CHBwI |
|
AH in adults |
|
CFVIId |
|
GT with refractoriness to platelets.1 |
|
|
|
|
|
| FEIBA® is indicated for bleed control and surgery in: |
|
CHAwI2,e |
|
CHBwI2,e |
 |
AH |
|
CFVIId |
|
GT with refractoriness to platelets.1 |
|
|
| eFEIBA® is also indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in CHAwI and CHBwI. |
| NovoSeven® RT contains only rFVIIa |
|
| NovoSeven® RT has just 1 main component1 |
| Recombinant activated Factor VII |
 |
|
|
|
|
| FEIBA® has 4 main components2 |
| Factors II, IX, and X mainly in non-activated form as well as mainly activated Factor VII |
| Factor VIII coagulant antigen (FVIII C:Ag) is present at a concentration of up to 1-6 units per mL of FEIBA® |
| Factors of the kinin-generating system are present only in trace amounts |
|
|
| NovoSeven® RT is a bypassing agent not made from human serum or human proteins. Recombinant manufacturing minimizes the risk of blood-borne pathogens compared to plasma-based treatments.1,3 |
|
|
| Do you have a novoMEDLINK™ account? |
| Complete a simple registration to receive the latest product news and education from Novo Nordisk. |
|
|
| With a novoMEDLINK™ account you can: |
 |
Order educational materials |
| |
|
 |
Access the latest product information |
| |
|
 |
Receive personalized updates |
|
|
|
| Indications and Usage |
|
NovoSeven® RT (coagulation Factor VIIa, recombinant) is a coagulation factor
indicated for:
|
| • |
Treatment of bleeding episodes and perioperative management in adults and children
with hemophilia A or B with inhibitors, congenital Factor VII (FVII)
deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet
transfusions, with or without antibodies to platelets
|
|
| • |
Treatment of bleeding episodes and perioperative management in adults with acquired
hemophilia
|
|
| Important Safety Information (cont’d) |
| Warnings and Precautions |
| • |
Hypersensitivity reactions, including anaphylaxis, can occur with
NovoSeven® RT. Patients with a known hypersensitivity to mouse,
hamster, or bovine proteins may be at a higher risk of hypersensitivity reactions.
Discontinue infusion and administer appropriate treatment when hypersensitivity
reactions occur
|
|
| • |
Factor VII deficient patients should be monitored for prothrombin time (PT) and
factor VII coagulant activity (FVII:C). If FVII:C fails to reach the expected level,
or PT is not corrected, or bleeding is not controlled after treatment with the
recommended doses, antibody formation may be suspected and analysis for antibodies
should be performed
|
|
| • |
Laboratory coagulation parameters (PT/INR, aPTT, FVII:C) have shown no direct
correlation to achieving hemostasis
|
|
| Adverse Reactions |
| • |
The most common and serious adverse reactions in clinical trials are thrombotic
events. Thrombotic adverse reactions following the administration of
NovoSeven® RT in clinical trials occurred in 4% of patients with
acquired hemophilia and 0.2% of bleeding episodes in patients with congenital
hemophilia
|
|
| Drug Interactions |
| • |
Thrombosis may occur if NovoSeven® RT is administered
concomitantly with Coagulation Factor XIII
|
|
| Please click here for Prescribing Information, including Boxed Warning. |
|
|
| 1. |
NovoSeven RT [package insert]. Plainsboro, NJ: Novo Nordisk Inc; 2020. |
| 2. |
FEIBA® [package insert]. Westlake Village, CA: Baxter Healthcare Corporation; 2024. |
| 3. |
National Hemophilia Foundation. MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Selected Disorders of the Coagulation System, #290. New York, NY: National Hemophilia Foundation; 2024 |
|
|
<%@ include view='hcpColoradoFooter' %>
|
| Please do not respond to this email. If you would like to contact us, please click here or call 1-800-727-6500. |
| UNSUBSCRIBE NOTICE |
| If you no longer want to receive communications from Novo Nordisk, click here to unsubscribe. You also may call us at 1-877-744-2579 or send us a letter that includes your full contact information (eg, name, email address, phone) to Novo Nordisk, 800 Scudders Mill Road, Plainsboro, New Jersey 08536. To better understand how Novo Nordisk values your privacy, see our Privacy Statement. |
|
NovoSeven® is a registered trademark of Novo Nordisk Health Care AG.
novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
All other trademarks, registered or unregistered, are the property of their respective owners.
© 2024 Novo Nordisk All rights reserved. US24NSVN00078 December 2024 |
 |
|
|
|
